Stock Market Update - January 19, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. VERO - Venus Concept Inc.
Price: $7.891 | Change: +451.82% ($6.461)
VERO caught significant attention with an impressive 451.82% gain, largely driven by major shareholder Madryn Asset Management. Madryn increased its ownership stake to a commanding 91% in mid-January 2026, granting it substantial control over Venus Concept Inc.'s future.
This heightened influence quickly led to discussions about aggressive operational cost reductions and the potential delisting of the company's common stock, signaling a strong commitment to restructuring for improved financial stability. Further bolstering confidence, Venus Concept also secured crucial debt relief and amended its loan agreement. Alongside these strategic financial moves, the recent FDA clearance for their Venus NOVA platform in late 2025 provided an underlying positive for product innovation.
2. CRKN - Crown ElectroKinetics Corp.
Price: $0.3 | Change: +172.73% ($0.19)
CRKN just rocketed up an incredible 172.73%! Crown ElectroKinetics Corp. stock experienced a dramatic surge, hitting $0.30, largely thanks to a smart strategic move by the company to shed some non-core assets.
On January 5, 2026, Crown ElectroKinetics completed the sale of its fiber optics construction business for $2.0 million. This move was all about streamlining operations and bringing in cash from assets that weren't central to their future. What's particularly noteworthy is that the company had previously faced the risk of being delisted from Nasdaq due to a low stock price. This clear step towards improving financial stability and focusing on core initiatives likely instilled fresh confidence in investors.
3. JFBR - Jeffs' Brands Ltd
Price: $1.29 | Change: +131.18% ($0.732)
JFBR experienced a staggering 131.18% gain, driven by a major strategic pivot. The company, formerly focused on e-commerce, is transforming into Nexera Technologies Ltd., shifting its attention to the burgeoning homeland security sector through its AI-driven subsidiary, KeepZone AI Inc.
A key catalyst for this surge was KeepZone AI's recent non-exclusive distribution agreement with STI Ltd., an Israeli developer of specialized security technologies. This partnership empowers KeepZone AI to distribute advanced products, including under-vehicle inspection systems and explosives detection devices, across Canada and Mexico, with provisions for temporary exclusivity periods for government and security bodies.
This strategic move positions KeepZone AI as a comprehensive provider of multi-layered security solutions in a market projected to reach $18.26 billion by 2034. Investors are clearly optimistic about the company's new direction and its potential within this critical sector.
4. JAGX - Jaguar Health, Inc.
Price: $1.43 | Change: +87.05% ($0.6655)
JAGX experienced an impressive 87.05% gain around January 20, 2026, primarily driven by a significant strategic move. The biotech company's subsidiary, Napo Pharmaceuticals, struck a U.S. licensing agreement with Future Pak, LLC. This deal makes Future Pak the exclusive marketer for Mytesi, an FDA-approved drug for HIV/AIDS-related diarrhea, and Canalevia-CA1, used for chemotherapy-induced diarrhea in dogs.
Jaguar Health stands to receive an $18 million upfront payment, with potential for up to an additional $20 million in milestone payments. This substantial non-dilutive capital infusion is crucial, as it’s expected to ease the company's cash flow constraints and allow them to fully concentrate on developing their rare-disease pipeline. Supporting this positive sentiment were favorable study outcomes for Crofelemer and an FDA grant for Canalevia-CA1, adding to investor confidence.
What makes this particularly interesting is how this strategic licensing agreement provides Jaguar Health with both immediate financial stability and a clearer, less burdened path to advance its innovative drug pipeline. It's a move designed to secure current revenue streams while freeing up resources for future growth.
5. TNMG - TNL Mediagene
Price: $3.91 | Change: +65.68% ($1.55)
TNMG experienced an impressive 65.68% gain around January 2026, fueled by a confluence of positive developments. This significant surge was primarily driven by an optimistic analyst report and several key strategic and product advancements.
A major catalyst was Benchmark analyst Fawne Jiang's assessment, who maintained a "Speculative Buy" rating and substantially raised the price target from $3.50 to $14.00, signaling strong confidence and potential upside. Further bolstering sentiment, TNL Mediagene's subsidiary secured a prominent partnership with the Japanese Ministry of Economy, Trade and Industry (METI) for a global fashion IP program, alongside the successful launch of a new digital media-commerce project that exceeded revenue targets.
What's particularly interesting is the company's move to integrate Natural Language Web (NLWeb) support across its digital media assets. This initiative enhances AI accessibility and opens doors for new monetization opportunities, including AI content licensing. This combination of strong analyst backing, strategic alliances, and innovative tech adoption painted a compelling picture for investors.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.